Our Platform

Revealing the true targets for next generation immunotherapies.

Technology Platform

We believe better cancer therapies are needed to transform people’s lives. We are developing accessible off-the-shelf cancer immunotherapies that will deliver durable benefits.

Learn more

Our technology platform builds on our proprietary and innovative approach to identifying shared, aberrantly expressed tumour-specific antigens (aeTSA), known as CryptigenTM TSAs, which we have exclusively licensed from the Université de Montréal (UdeM), along with the rights to exploit large sets of CryptigenTM TSAs in solid and hematological cancers.

As our proprietary CryptigenTM TSAs are uniquely presented by cancer cells and broadly shared within cancer types, they provide a tumour-specific target for immunotherapies that are anticipated to kill malignant cells while sparing non-cancerous cells, providing the hope of significant therapeutic effects for large patient populations with minimal side effects.

Until recently, these hidden antigens have largely escaped the attention of the world’s cancer researchers, but their significance has now been brought to light in research by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer of UdeM.

Our innovative approach to finding these hidden CryptigenTM TSAs is based on an empirically-anchored combination of immunopeptidomics, mass spectrometry, genomics, and bioinformatics.

Therapeutic Focus

We are building our own pipeline in oncology developed from novel, untapped aberrantly expressed tumour-specific antigens (aeTSAs), which we call CryptigenTM TSAs, licenced from the Université de Montréal, along with the rights to exploit the large sets of already-identified CryptigenTM TSAs.

We are also actively expanding the identification of additional sets of CryptigenTM TSAs in multiple cancer indications.

Using a robust empirical approach, we are prioritising CryptigenTM TSAs as targets against which we will develop lead pipeline assets for use as immunotherapeutics in at least two cancer indications.

We will translate our CryptigenTM TSA discoveries into novel therapeutics deploying the best modalities available to help cancer patients achieve durable benefits, including cancer vaccines, TCR-based biologics, or T cell therapies.

Partnering Opportunities

We will explore a variety of early and longer-term value creation strategies including looking to out-license our technology (individual CryptigenTM TSAs for immune-cell engagers or cell therapies or sets for therapeutic vaccines) to partners at vaccine technology and cell therapy companies, for clinical development in oncology.

If you are interested in collaborating with us to exploit the full therapeutic potential of our CryptigenTM TSAs, please contact us on info@epitopea.com (or use the button below) to discuss partnering opportunities.

Publications

Title	Year	Journal	Authors	View
Breast cancer immunopeptidomes contain numerous shared tumor antigens	2024	The Journal of Clinical Investigation	Eralda Kina, Et al	View
Induced pluripotent stem cells display a distinct set of MHC I-associated peptides shared by human cancers	2022	Cell Reports	Anca Apavaloaei, Et al	View
Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability	2022	MCP Online	Jenna Cleyle, Et al	View
Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes	2021	Immunity: A Cell Press journal	Grégory Ehx, Et al	View
Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer	2020	Cancer Immunology Research	Qingchuan Zhao, Et al	View
Noncoding regions are the main source of targetable tumor-specific antigens	2018	Science Translational Medicine	Céline M. Laumont, Et al	View

About Us

Platform

News & Events

Language

Our Platform

Technology Platform

Therapeutic Focus

Partnering Opportunities

Publications